HEBEI SENLANG BIOTECHNOLOGY
Hebei Senlang Biotechnology is focused on the treatment of immune cells new technology development and application of high-tech enterprises.The company has the CAR-T research base (Senrang CAR-T Research Center) in North China, and has formed a high-barrier technology platform such as innovative CAR structural design, virus and cell culture , which can take into account technical research and development, hospital clinical application Provide high-quality and effective cellular immunotherapy support for hematological tumors, solid tumors and other tumor diseases, immune system diseases and other patients.
HEBEI SENLANG BIOTECHNOLOGY
Industry:
Biotechnology Health Care Pharmaceutical
Founded:
2016-01-01
Address:
Dongguan, Hebei, China
Country:
China
Website Url:
http://www.senlangbio.com
Status:
Active
Contact:
+86-311-82970975
Total Funding:
29.61 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible Mobile Non Scaleable Content Nginx Amazon Apple Mobile Web App Capable DigiCert SSL Apple Mobile Web App Status Bar Style GeoTrust SSL Amazon California Region
Similar Organizations
EpiVax
EpiVax is an immunology company developing comprehensive analytical capabilities in the field of computational immunology.
Current Employees Featured
Founder
Investors List
Qianhai Fund of Funds
Qianhai Fund of Funds investment in Private Equity Round - Hebei Senlang Biotechnology
Guochuang Investment
Guochuang Investment investment in Series B - Hebei Senlang Biotechnology
Hebei Xianchuang
Hebei Xianchuang investment in Series B - Hebei Senlang Biotechnology
More informations about "Hebei Senlang Biotechnology"
SenlangBio
河北森朗生物科技有限公司是一家专注于细胞治疗新技术研发与应用的高科技生物医药企业。See details»
Hebei Senlang Biotechnology - Crunchbase Company Profile
Hebei Senlang Biotechnology is focused on the treatment of immune cells new technology development and application of high-tech enterprises.The company has the CAR-T research …See details»
公司简介-河北森朗生物科技有限公司 - SenlangBio
河北森朗生物科技有限公司，成立于2016年，公司专注于细胞治疗新技术研发与应用的高科技生物医药企业，致力于恶性肿瘤的精准治疗。公司创始人兼首席科学家李建强博士拥有多年海外研发工作经历，曾在洛杉矶希望之城癌症研究中心、 …See details»
Hebei Senlangbio Biotechnology Co., Ltd. - Drug pipelines, Patents ...
Explore Hebei Senlangbio Biotechnology Co., Ltd. with its drug pipeline, therapeutic area, technology platform, 38 clinical trials, 5 news, and 1 literature, Disease Domain:Neoplasms, …See details»
Hebei Senlangbio Biotechnology Co., Ltd. - synapse.zhihuiya.com
了解Hebei Senlangbio Biotechnology Co., Ltd. (河北森朗生物科技有限公司)公司的药物管线，治疗领域，技术平台，以及它的38项临床试验, 49篇新闻和1篇文献，疾病领域:肿瘤，血液及淋 …See details»
Avalon to buy China’s Senlang for cell therapies - BioProcess Insider
Jun 16, 2021 According to SenlangBio, the facility has capacity for the production of lentiviral vectors, plasmids, T-cell cultures as well as validation bio-assays. Avalon CEO David Jin said, …See details»
Company news-Hebei Senlang Biotechnology Co., Ltd.
2022-08-05 重磅！森朗生物Senl_B19自体T细胞注射液产品I期临床研究在北京大学人民医院正式启动. 重磅！森朗生物Senl_B19自体T细胞注射液产品I期临床研究在北京大学人民医院正式启 …See details»
Avalon GloboCare says SenlangBio will enhance its capabilities in …
Jun 28, 2021 Avalon GloboCare Corp (NASDAQ:AVCO) told shareholders that its acquisition of Hebei Senlang Biotechnology Co Ltd, the largest cell therapy company in northern China in …See details»
Avalon GloboCare CEO Provides Letter to Update Shareholders
Jun 28, 2021 SenlangBio Generated Revenue of USD $1.2 Million for the Three Months Ended March 31, 2021 and Projects $5 Million to $7 Million in Revenue for the Full Year 2021See details»
Avalon GloboCare Acquires SenlangBio - citybiz
Jun 14, 2021 Avalon and SenlangBio have also entered into agreements with an institutional healthcare investor which has committed to invest approximately USD $30 million in exchange …See details»
Avalon GloboCare inks definitive agreement to acquire Chinese …
Jun 14, 2021 Jin will remain CEO of Avalon, as well as co-CEO of the SenlangBio subsidiary. Jianqiang Li, CSO of SenlangBio, will be named the chief technology officer of Avalon and join …See details»
Cell Therapy Developer Senlang Bio Raises CNY 200 Million in New ...
May 18, 2022 Founded in 2016, Hebei Senlang Bio is a clinical-stage biotechnology company dedicated to utilizing cell and gene engineering technologies to generate innovative and …See details»
Avalon GloboCare Announces its Planned Acquisition Target, …
Jul 1, 2021 SenlangBio’s anti-EphA2 CAR-T is a first-in-class cellular therapy and to our best knowledge, the first ever EphA2-targeted CAR-T with reported clinical trial data. Erythropoietin …See details»
Avalon GloboCare Announces Execution of Purchase Agreement …
Jun 14, 2021 SenlangBio, a world-class cell therapy company, has developed a robust pipeline which includes 15 autologous and universal (“off-the-shelf”) CAR-T and CAR-γδT cell therapy …See details»
CAR-T bridging to allo-HSCT as a treatment strategy for relapsed …
A .gov website belongs to an official government organization in the United States. Secure .gov websites use HTTPS A lock ... The CAR-T cells were engineered by Hebei Senlangbio …See details»
Avalon Globocare to acquire SenlangBio in all-stock deal
Jun 14, 2021 SenlangBio is currently the largest cell therapy company in Northern China in terms of bio-manufacturing scale, breadth and depth of clinical development programs, and …See details»
SENL-104 - Drug Targets, Indications, Patents - Synapse - Patsnap
SENL-104: a CD19 inhibitors Drug, Initially developed by Hebei Senlangbio Biotechnology Co., Ltd., Now, its global highest R&D status is Preclinical, Mechanism: CD19 inhibitors(B …See details»
Avalon GloboCare Announces Execution of Purchase Agreement
Jun 14, 2021 Avalon and SenlangBio have also entered into agreements with an institutional healthcare investor which has committed to invest approximately USD $30 million in exchange …See details»
Avalon GloboCare Announces its Planned Acquisition Target, …
Jul 1, 2021 SenlangBio’s anti-EphA2 CAR-T is a first-in-class cellular therapy and to our best knowledge, the first ever EphA2-targeted CAR-T with reported clinical trial data. Erythropoietin …See details»
SENL401 - Drug Targets, Indications, Patents - Synapse - Patsnap
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.See details»